6 weeks on semaglutide My Epic Taper Journey! Astonishing Ozempic Weight Loss Transformation! What I have learned after

GLP-1R agonists impact visceral pain, with specific relevance to IBS

Weight loss peptide therapy produces effective results through several key mechanisms, detailed as follows: Appetite Regulation: GLP-1 receptor agonists affect the brain regions responsible for hunger control, reducing appetite, and promoting feelings of fullness

drug should appear clear and colorless Do not use semaglutide if particulate matter and coloration observed Instructions for Wegovy SC Injection (Video, Click Play) Side Effects Very Common: may affect more than 1 in 10 people feeling or being sick (nausea or vomiting) diarrhea constipation stomach pain feeling weak or tired headache these usually goes away over time Common: may affect up to 1 in 10 people feeling dizzy upset stomach or indigestion burping gas (flatulence) bloating of the stomach inflamed stomach (gastritis) the signs include stomach-ache, feeling sick (nausea) or being sick (vomiting) reflux or heartburn also called gastro-esophageal reflux disease hair loss injection site reactions low blood sugar (hypoglycaemia) in patients with diabetes low blood pressure increase of pancreatic enzymes (such as lipase) shown in blood tests hemorrhoids upset stomach or indigestion burping gas (flatulence) bloating of the stomach inflamed stomach (gastritis) the signs include stomach-ache, feeling sick (nausea) or being sick (vomiting) reflux or heartburn also called gastro-esophageal reflux disease hair loss injection site reactions low blood sugar (hypoglycaemia) in patients with diabetes low blood pressure increase of pancreatic enzymes (such as lipase) shown in blood tests hemorrhoids Uncommon: may affect up to 1 in 100 people fast heartbeat increase of pancreatic enzymes (such as amylase) shown in blood tests feeling faint or fainting/passing out low blood sugar (hypoglycaemia) in patients without diabetes Children and Adolescents Not recommended in children and adolescents under 18 years of age as the safety and efficacy in this age group have not yet been studied

doi: 10.1016/j.jhep.2019.06.021 47 DrodKMaciejczykMKarakulakMebrowskaEChabowskiAendzian-PiotrowskaM

Andere Daten werden automatisch beim Besuch der Website durch unsere IT-Systeme erfasst